Trials / Completed
CompletedNCT05129462
Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Evaluated the correlation between the qualitative test results of Xiamen Aide PD-L1 antibody reagent (immunohistochemistry) and the efficacy of Keytruda single-agent therapy, and the research data is used to support the registration and marketing of the assessment reagent
Conditions
Timeline
- Start date
- 2018-08-05
- Primary completion
- 2021-09-05
- Completion
- 2021-10-01
- First posted
- 2021-11-22
- Last updated
- 2021-12-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05129462. Inclusion in this directory is not an endorsement.